Although dendritic cell (DC)-based immunotherapy is considered a promising approach for cancer treatment, a large quantity of DC vaccine is required for effective sensitization/ activation of immune cells because of the poor migratory ability of administered DCs into regional lymphoid tissue. In this study, we created a DC vaccine sufficiently transduced with CC chemokine receptor-7 gene (CCR7/DCs) by applying RGD fiber-mutant adenovirus vector (AdRGD), and investigated its immunological characteristics and therapeutic efficacy. CCR7/DCs acquired strong chemotactic activity for CC chemokine ligand-21 (CCL21) and exhibited an immunophenotype similar to mature DCs but not immature DCs with regard to major histocompatibility complex/costimulatory molecule-expression levels and allogenic T cell proliferation-stimulating ability, while maintaining inherent endocytotic activity. Importantly, CCR7/DCs injected intradermally into mice could accumulate in draining lymph nodes about 5.5-fold more efficiently than control AdRGD-applied DCs. Reflecting these properties of CCR7/DCs, DC vaccine genetically engineered to simultaneously express endogenous antigen and CCR7 could elicit more effective antigenspecific immune response in vivo using a lower dosage than DC vaccine transduced with antigen alone. Therefore, the application of CCR7/DCs having positive migratory ability to lymphoid tissues may contribute to reduction of efforts and costs associated with DC vaccine preparation by considerably reducing the DC vaccine dosage needed to achieve effective treatment by DC-based immunotherapy.
Introduction
Immunotherapy using dendritic cells (DCs), which play a critical role in control of both acquired and innate immune responses in the living body, is studied energetically in many research organizations aiming to immunologically eradicate cancer. In addition, several cancer immunotherapy protocols using DC vaccine introduced with tumor-associated antigen (TAA) advanced to the clinical study phase. [1] [2] [3] [4] However, since currently available DC-based immunotherapy has not demonstrated exceptional therapeutic effects in these clinical studies, the development of a novel approach capable of improving the efficacy of this promising strategy for cancer treatment is eagerly awaited.
DCs are widely distributed over peripheral tissues, where they catch invading antigens by full endocytotic activity, characteristic of an immature state. The phenotype of DCs internalizing antigens changes to a mature state in response to these inflammatory stimuli. Subsequently, they process the antigens into the peptides presented on major histocompatibility complex (MHC) molecules, migrate into draining lymph nodes (LNs) via afferent lymphatic venules, and induce primary immune responses through antigen presentation to T cells. [5] [6] [7] On the basis of these serial immune mechanisms, the degree of administered DC vaccine accumulation in lymphoid tissues is a factor in enhancing or restricting therapeutic effects in DC-based immunotherapy.
In recent years, identification and functional analysis of chemokines/chemokine receptors, which regulate relevant leukocyte migration and invasion into tissues, have progressed remarkably, and the chemokine-chemokine receptor coupling in DC migration from peripheral tissue to lymphoid tissue has been elucidated. Gunn et al 8 found that DC migration to secondary lymphoid tissues was inhibited in CC chemokine ligand-21 (CCL21) expression-defective plt/plt mice. Likewise, Förster et al 9 reported that inhibition of DC migration to secondary lymphoid tissues occurred in CC chemokine receptor-7 (CCR7)-knockout mice. Based on these results, the association between CCL21, which is pro-duced and secreted constitutively in lymphoid tissues and lymphatic vessels, and CCR7, a seven-transmembrane domain G-protein-coupled receptor whose expression is enhanced on the surface of maturing DCs, has been shown to play a central role in control of DC migration from the peripheral tissue to lymphoid tissues. Therefore, DCs, which are not only introduced with antigens but also exhibit enhanced CCR7 expression, may positively migrate to lymphoid tissue and efficiently activate the host's immune system after administration to a living body. Efficient CCR7-gene transduction to DCs is proposed as a preparatory method for this novel 'lymphoid tissue-directivity DC' vaccine.
Efficient gene transduction to DCs is difficult in any conventional vector system including adenovirus vector (Ad), which could transfect in a wide variety of cells and tissues. 10 In this regard, we succeeded in establishing highly efficient gene transduction to DCs by applying RGD fiber-mutant Ad (AdRGD), [11] [12] [13] [14] and clarified that vaccination with DCs transduced with TAA gene using AdRGD induced considerable antitumor effect based on activation of TAA-specific cytotoxic T lymphocytes (CTLs) in mice. 12, 14 Our results not only revealed that AdRGD is very useful in antigen gene delivery to DCs, but also opened up new potentiality for genetically enhancing the immunological functions of DCs by making use of the predominance of AdRGD in gene transduction efficiency to DCs. Thus, in the present study, we first constructed an AdRGD-carrying CCR7 gene (AdRGD-CCR7), and investigated the immunological properties and vaccine efficacy of murine bone marrowderived DCs modified with AdRGD-CCR7 in order to create a 'lymphoid tissue-directivity DC' vaccine.
Results

Gene transduction into DCs by AdRGD-CCR7
We examined the cytopathic effects of gene transduction using AdRGD-CCR7 to DCs by MTT assay. AdRGD-CCR7 did not injure DCs with a vector dose of 100 multiplicities of infection (MOI) or less, whereas viability of DCs was slightly reduced by using AdRGD-CCR7 at 200 MOI (data not shown). Thus, CCR7 gene expression was evaluated by semiquantitative reverse transcriptionpolymerase chain reaction (RT-PCR) analysis in DCs transduced with AdRGD-CCR7 at 100 MOI or less. The CCR7 mRNA level of lipopolysaccharide-stimulated DCs (LPS/DCs) or Luc/DCs transduced with AdRGD-Luc (luciferase-expressing control vector) at 50 MOI did not show a remarkable change in comparison with that of mock (immature) DCs at 24 h post-treatment ( Figure 1a ). Figure 1 RT-PCR and flow cytometric analysis for mouse CCR7 expression levels. DCs were transduced with AdRGD-CCR7 or AdRGD-Luc at 50 MOI (a and c) or the indicated MOI (b). These transduced cells, LPS-stimulated DCs, and mock DCs were cultured for 24 h (a and c) or the indicated period (b) in GM-CSF-free medium. (a and b) Total RNA was isolated from these DCs, and then mouse CCR7 mRNA expression was assessed by RT-PCR analysis. Relative CCR7 mRNA expression was calculated as ratio of the densitometric units of PCR products derived from CCR7 transcripts to the densitometric units of PCR products derived from b-actin transcripts. Data are presented as mean7s.d. of results from three independent experiments. (c) Flow cytometric analysis was performed by using anti-mouse CCR7 antibody. Negative control represents mock DCs stained by second antibody alone. The data are representative of two independent experiments, and the % value and the numerical value indicated in the upper part of each panel express % of M1-gated cells and mean fluorescence intensity (MFI), respectively.
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On the other hand, CCR7/DCs prepared with AdRGD-CCR7 at 50 MOI were able to express CCR7 mRNA at a level more than double that of mock DCs. In addition, we analyzed the changes in CCR7 mRNA expression over time in CCR7/DCs transduced at various vector doses ( Figure 1b) . It was revealed that CCR7 mRNA expression in CCR7/DCs increased in a vector dose-dependent manner, and highest levels were observed at 24 h after gene transduction. Moreover, flow cytometric analysis using anti-mouse CCR7 polyclonal antibody showed that most of the CCR7/DCs, which were prepared with AdRGD-CCR7 at 50 MOI and then cultured for 24 h, expressed CCR7 protein on their surface, whereas few CCR7-positive cells were detected in mock DCs, LPS/ DCs, and Luc/DCs ( Figure 1c) . Next, we evaluated the chemotactic activity of CCR7/ DCs for CCL21 by in vitro chemotaxis assay in order to confirm functional CCR7 expression on the cell surface. Under transductional conditions at an MOI of 50, the number of migrating CCR7/DCs cultured for 24 h markedly increased with increasing CCL21 concentration, whereas Luc/DCs, LPS/DCs, and mock DCs remained at low levels despite CCL21 stimulation ( Figure 2a ). Furthermore, as was observed for RT-PCR analysis in Figure 1b , the chemotactic activity of CCR7/ DCs for CCL21 was enhanced with increasing AdRGD-CCR7 dose during transduction (Figure 2b ). These results clearly demonstrated that functional CCR7, which could promote migration of DCs in response to a CCL21 concentration gradient, was expressed on the CCR7/DC surface, and that transduction of the chemokine receptor gene by AdRGD could modify chemokine responsiveness of DCs.
Immunological properties of CCR7/DCs
We analyzed the immunological characteristics of CCR7/ DCs prepared with AdRGD-CCR7 at 50 MOI. At first, the expression levels of MHC/costimulatory molecules in CCR7/DCs cultured for 24 h were analyzed by flow cytometry (Figure 3a ). In comparison with mock DCs, CCR7/DCs and Luc/DCs exhibited upregulated expression of all tested surface marker molecules, which play critical roles in the sensitization/activation of T cells, as is seen in mature LPS/DCs. In particular, the expression levels of CD40 and CD86 were dramatically enhanced by gene transduction using AdRGD. This result agreed with our previous report demonstrating that transduction using AdRGD, irrespective of the type of inserted transgene, could enhance the expression of MHC/ costimulatory molecules on DCs. 13 Moreover, CCR7/ DCs were able to stimulate proliferation of allogenic naive T cells in mixed leukocyte reaction (MLR) more effectively than mock DCs, and the stimulatory ability of CCR7/DCs, Luc/DCs, and LPS/DCs was equal at a responder/stimulator ratio of 5 ( Figure 3b) .
The level of fluorescein isothiocyanate (FITC)-dextran uptake in CCR7/DCs was estimated as an index of their endocytotic activity (Figure 3c ). Excellent endocytosis for FITC-dextran was observed in mock DCs incubated at 371C, whereas fluorescence intensity derived from internalized FITC-dextran was drastically decreased by 41C incubation or LPS-driving maturation. On the other hand, FITC-dextran-uptake levels in CCR7/DCs and Luc/DCs, which were cultured for 24 h after gene transduction, were comparable to those in mock DCs.
Taken together, these results demonstrate that gene transduction using AdRGD-CCR7 did not eliminate the antigen-presenting cell (APC) function of DCs; rather, CCR7/DCs acquired an immunophenotype similar to mature DCs while maintaining high endocytotic capacity. Additionally, these immunological characteristics of CCR7/DCs were similar at 48 h post-transduction (data not shown).
Accumulation of CCR7/DCs in regional LN
DCs derived from enhanced green fluorescent proteintransgenic (EGFP-Tg) mice were transduced with AdRGD-CCR7 or AdRGD-Luc at 50 MOI and then cultured for 24 h. These EGFP-positive CCR7/DCs, Luc/DCs, and mock DCs were intradermally injected into the flank of wild-type mice, and their accumulation in the draining inguinal LN was compared at 48 h postadministration by flow cytometric analysis (Figure 4) . In all mice, the EGFP-positive DCs were not detected in the inguinal LNs contralateral to the DC-administration site (data not shown). More than double the number of EGFP-positive DCs was detected in regional LN cells prepared from mice injected with Luc/DCs, as compared Figure 3a and b. Importantly, CCR7/DCs could migrate approximately 5.5-and 15-fold more efficiently into the regional LN than Luc/DCs and mock DCs, respectively, clearly demonstrating that CCR7 gene transduction using AdRGD was useful technology to accelerate the accumulation of DC vaccine in regional LN.
Vaccine efficacy of DCs co-transduced with antigen and CCR7
In order to evaluate the potency of CCR7/DCs as vaccine carriers, we prepared the DC vaccine co-transduced with CCR7 gene and ovalbumin (OVA), model antigen, gene using AdRGD. As shown in Figure 5 , DCs combined with AdRGD-OVA and AdRGD-CCR7 could present OVA peptides via MHC class I molecules at levels equal to DCs transduced with AdRGD-OVA alone. On the other hand, the OVA-presentation level in DCs cotransduced with AdRGD-OVA and AdRGD-Luc decreased by half. These data revealed that CCR7 gene transduction did not affect the MHC class I-presentation pathway for antigens endogenously and simultaneously expressed in DCs, and suggested that the proteins accumulating in the cytoplasm and the membranelocalized receptors, such as luciferase and CCR7, respectively, might induce different methods for processing co-expressed endogenous antigens in DCs.
We compared the antitumor effects of DCs cotransduced with gp100, a melanoma-associated antigen, and CCR7 (gp100+CCR7/DCs) and DCs transduced with AdRGD-gp100 alone (gp100/DCs) in the murine 
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N Okada et al B16BL6 melanoma model. Obvious growth suppression of B16BL6 tumor challenge was achieved in mice vaccinated with gp100/DCs, as shown in our previous report, 14 whereas immunization with mock DCs or CCR7/DCs was not effective ( Figure 6 ). This vaccine efficacy of gp100/DCs depended on the administered DC dosage. Notably, equal antitumor effects were observed in groups vaccinated with 2 Â 10 5 gp100+CCR7/DCs and with 5 Â 10 5 gp100/DCs, and vaccination with 5 Â 10 5 gp100+CCR7/DCs caused extensive inhibition of B16BL6 tumor growth. Thus, we assessed B16BL6-specific CTL activity in mice vaccinated with gp100+CCR7/DCs or gp100/DCs by europium (Eu)-release assay (Figure 7a ). The effector cells prepared from mice vaccinated with gp100/DCs could strongly injure B16BL6 cells, as we reported previously.
14 In addition, the effector cells in all groups did not induce lysis of YAC-1 cells, which are highly susceptible to NK activities, and H-2 haplotype-matched irrelevant EL4 thymoma cells (data not shown). B16BL6-specific cytotoxic activity increased in splenocytes from mice vaccinated with gp100+CCR7/DCs, depending on administered DC-dosage, and cytotoxicity exceeded that observed in the group treated with gp100/DCs at same dosage (5 Â 10 5 cells/mouse). Furthermore, re-stimulated splenocytes from mice vaccinated with gp100+CCR7/ DCs at 2 or 5 Â 10 5 cells/mouse exhibited higher frequency of interferon-g (IFN-g)-producing cells in ELISPOT assay in comparison with those from 5 Â 10 5 gp100/DCs-immunized mice (Figure 7b ). Taken together, these data indicated that the induction of a TAA-specific immune response can be potentiated by the improved migration of TAA-loaded DC vaccine from the administration site to lymphoid tissue.
Discussion
The development of a vaccine for cancer treatment aims for sufficient induction of the tumor-specific immune response, in which antitumor CTLs play a central role, to a level capable of tumor rejection and regression. The Vaccine efficacy of DCs co-transduced with CCR7 and gp100 gene against B16BL6 melanoma challenge. CCR7/DCs, gp100/DCs, and gp100+CCR7/DCs were prepared using corresponding vectors at 25 MOI, and then cultured for 24 h. C57BL/6 mice were immunized by intradermal injection of transduced DCs into the left flank at the indicated cell dosage, and then 4 Â 10 5 B16BL6 melanoma cells were inoculated into the right flank of the mice at 1 week post-vaccination. The tumor sizes were assessed using microcalipers three times per week. Each point represents the mean7s.e. of 5-10 mice. Figure 4 Migration of CCR7/DCs from administration site to draining LN. EGFP-Tg DCs were transduced with AdRGD-CCR7 or AdRGD-Luc at 50 MOI, and then were cultured for 24 h. These transduced cells and mock DCs were intradermally injected into the left flank of C57BL/6 mice at 2 Â 10 6 cells/50 ml. After 2 days, the draining inguinal LNs were collected from these mice, and a single-cell suspension was prepared and stained by indirect immunofluorescence using anti-CD11c monoclonal antibody. The abundance of EGFP +
CD11c
+ DCs was assessed by flow cytometric analysis acquiring 500 000 events. The number of DCs that had migrated into draining LNs was calculated by multiplying the EGFP + CD11c
+ DC frequency by the total number of isolated LN cells. Data are presented as mean7s.e. of results from four mice.
CCR7-transduced DC vaccine N Okada et al efficient priming and subsequent activation of antitumor CTLs requires the processing and presentation of TAAs as peptide fragments in the context of appropriate MHC class I molecules by APCs. 15 DCs are the most potent APCs and are uniquely capable of presenting novel antigens to naive T cells to initiate and modulate immune responses. [5] [6] [7] Owing to these properties, TAA-loaded DCs are considered promising vaccine carriers in immune intervention strategies against cancer. However, very few DCs in currently available DC-based immunotherapies are capable of migrating from an administration site to regional lymphoid tissue, [16] [17] [18] where they present MHC class I-and II-restricted peptides to naive T cells, because optimal DC conditioning for enhancing migratory ability is not yet established. Therefore, increasing the migratory ability of a DC vaccine toward lymphoid tissues would remarkably improve the efficacy of DC-based immunotherapy because priming/activation of immune effector cells would be significantly promoted. In the present study, we focused on the chemokine receptor, CCR7, which manages facilitated DC migration to lymphoid tissues, and attempted to create a DC vaccine that sufficiently expressed CCR7 on the surface by gene transduction.
A vector system that can effectively deliver a foreign gene to DCs is essential for preparing a genetically modified-DC vaccine. We have demonstrated that AdRGD can enhance gene transduction efficiency against murine and human DCs as compared with conventional Ad because of the expression of the RGD sequence, the av-integrin-targeting peptide, at the HI loop in the fiber knob.
11-14 Therefore, we constructed AdRGD-CCR7, which carried the expression cassette containing mouse CCR7 cDNA under the control of the cytomegalovirus promoter, and confirmed the vector's performance. RT-PCR analysis indicated that transfection using AdRGD-CCR7 allowed murine bone marrowderived DCs to express abundant CCR7 mRNA, and CCR7 mRNA expression in CCR7/DCs was the highest at 24 h after gene transduction. Furthermore, CCR7/DCs cultured for 24 h exhibited sufficient CCR7 protein expression on the cell surface in flow cytometric analysis and demonstrated strong migratory ability toward CCL21, a CCR7 ligand secreted constitutively from lymphoid tissues, depending on both CCL21 concentration in a 4 h chemotaxis assay and AdRGD-CCR7 dose in transfection. That is, efficient CCR7-gene transduction into DCs by AdRGD reinforced surface expression of CCR7, which sensed a CCL21 concentration gradient and transmitted intracellular signals associated with migration in their original biologically active form. Although DCs generally enhance the expression of CCR7 and acquire migratory ability to lymphoid tissues by various maturation stimuli, an increase in CCR7 mRNA levels and enhancement of migratory activity toward CCL21 were not observed in LPS/DCs, contrary to our expectation. Granucci et al 19 reported that DCs stimulated with LPS significantly decreased their intrinsic migratory ability and increased the antigen uptake function at 1-2 h post-stimulation. This phenomenon probably represents the in vivo stage during which DCs remain at an inflammation site caused by the components of invading bacteria, such as LPS, and capture antigens by full endocytosis. In addition, Granucci et al 19 demonstrated that, at around 4 h after LPS activation, DCs recovered their migratory ability and started to progressively lose antigen uptake function until they reached the mature stage in which LPS/DCs showed poor antigen uptake and migratory activity. Therefore, because in the present study we tested the responses 24 h after LPS stimulation, low CCR7 mRNA levels and poor migratory response to CCL21 by LPS/DCs may have been observed because tests were run after the optimal time point, suggesting that the control of DC-migratory activity by LPS stimulation is difficult.
DCs are strong initiators of defense mechanisms that combat infectious diseases and cancer, but, in their role as APCs, DCs are also involved in immune suppression and immune tolerance. [20] [21] [22] [23] In their induction of a positive immune response, immature DCs capture invading antigens at peripheral locations and are then activated by inflammatory stimuli, such as interleukin (IL)-1b, tumor necrosis factor-a, and bacterial components, to migrate to T-cell-rich areas in regional LN. In these processes, DCs enhance the expression of MHC/ costimulatory molecules, which is essential for T-cell surface sensitization for effective induction of T-cell- Figure 7 CTL activity and the frequency of IFN-g-producing cells in splenocytes from mice immunized with DCs cotransduced with CCR7 and gp100 gene by AdRGD. gp100/DCs and gp100+CCR7/DCs were prepared using corresponding vectors at 25 MOI, and then cultured for 24 h. These transduced cells and mock DCs were vaccinated once intradermally into C57BL/6 mice at the indicated cell dosage. At 1 week after immunization, nonadherent splenocytes were prepared from these mice, and then were restimulated in vitro for 5 days with IFN-g-stimulated and MMCinactivated B16BL6 cells. (a) A cytolytic assay using the re-stimulated splenocytes (effector cells) was performed against IFN-g-stimulated B16BL6 cells (target cells). The data represent the mean7s.e. of four independent cultures from four individual mice. (b) IFN-g-producing cells in re-stimulated splenocytes were evaluated by mouse IFN-g ELISPOT assay. The data represent the mean7s.d. of results from four mice.
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N Okada et al dependent primary immune responses. On the other hand, in negative immune regulation, immature DCs take up resident biological materials or apoptotic bodies and present processing peptides without acquiring activated phenotypes during migration to regional LN. 24, 25 Therefore, a full analysis and understanding of immunological characteristics of DC vaccine is imperative for the development of DC-based immunotherapy because the polarity of the immune response is greatly influenced by the activated state of DCs during T-cell sensitization. CCR7/DCs created in the present study maintained inherent endocytotic activity, suggesting that CCR7/DCs administered into tumor tissue can capture necrotic or apoptotic tumor cell fragments and may induce TAA-specific immune responses. Yanagawa et al 26 reported that internalization of FITC-dextran in murine mature DCs increased in the presence of CCR7 ligand, CCL19 or CCL21. These results support the notion that CCL21, secreted from lymphatic vessels located near a tumor, may encourage uptake of tumor cell fragments by CCR7/DCs injected into the tumor tissue. Although high endocytotic activity is a characteristic feature of immature DCs, flow cytometric analysis indicated that CCR7/ DCs enhanced expression of MHC/costimulatory molecules and allo-MLR suggested the reinforcement of T-cell proliferation-stimulating ability. These results agreed with our previous report demonstrating that transduction using AdRGD could enhance the maturation status of DCs, 13 strongly suggesting that CCR7 gene transduction using AdRGD did not inhibit the original APC characteristics of DCs and that CCR7/DCs can function as a useful vaccine possessing sufficient T-cell activation ability in vivo.
Although a technique to label DCs with radioisotopes or fluorescent substances is frequently used for evaluating in vivo kinetics of administered DC vaccines, [27] [28] [29] [30] [31] [32] release via exosomes or leakage of the labeling material from DCs complicates the analysis. Eggert et al 33 reported that application of EGFP-Tg mouse-derived DCs avoided this problem and enabled simple evaluation and analysis of the kinetics of administered DCs without the need for labeling. Thus, we investigated the migratory ability of CCR7/DCs by flow cytometric analysis of regional LN cells prepared from mice intradermally injected with transduced EGFP-Tg mouse-derived DCs. At 48 h postinjection, regional LNs that served as administration sites for CCR7/DCs were obviously larger than contralateral LNs under macroscopic observation, and the frequency of EGFP + CD11c + DCs in regional LN cells was 1.9370.54, 0.5770.19, and 0.1270.04% (mean7s.e.) for CCR7/DCs-, Luc/DCs-, and mock DCs-injected mice, respectively. In addition, we could prepare more cells from regional LN in CCR7/DCs-injected mice than from the Luc/DC or mock DC groups, suggesting that not only administered DCs but also other immune cells, such as T cells, might accumulate in regional LN in mice injected with CCR7/DCs.
Previously, we demonstrated that immunization with DCs efficiently transduced with gp100 gene by AdRGD could significantly inhibit the growth and lung metastasis of murine B16BL6 melanoma in vivo.
14 In order to actually evaluate the predominancy of CCR7-transduced DCs as a vaccine carrier in vivo, we investigated anti-B16BL6 melanoma effects in mice vaccinated with DCs genetically engineered to simultaneously express gp100 and CCR7. Although antigen presentation via MHC class I molecules in the experiment using AdRGD-OVA was the same for DCs transduced with OVA gene alone and co-transduced with OVA and CCR7 gene, immunization with gp100+CCR7/DCs could more effectively suppress growth of B16BL6 tumors than vaccination with gp100/ DCs. Furthermore, DC vaccine co-transduced with the TAA gene and the CCR7 gene effectively induced TAAspecific and IFN-g-producing CTLs using a lower dosage than conventional DC vaccine transduced with TAA gene alone. These data suggest that augmentation of lymphoid tissue directivity of DCs by efficient CCR7-gene transduction can reduce the DC vaccine dosage that is needed to elicit efficacious therapeutic effects in DCbased immunotherapy. In other words, this method may considerably reduce the cost, time, and effort for DC vaccine preparation and relieve the patient from the burden of frequent blood drawing for DC isolation.
In conclusion, our data strongly suggested that in vivo kinetic control of DC vaccine, namely the establishment of an active DC delivery system to lymphoid tissues, was very useful for improving the efficacy of DC-based immunotherapy. We expect that superior lymphoid tissue accumulation of DCs transduced with the CCR7 gene is advantageous for a vaccine carrier because of efficient activation of immune effector cells in regional LNs and a rapid supply of activated effector cells to the whole body. Recently, optimized DC conditioning, which includes stimulation of antigen-presenting DCs with various cytokines or ligand molecules, has been investigated for the development of more effective DC-based immunotherapy. Several reports demonstrated that DC stimulation by prostaglandin E 2 34-36 or the pre-induction of inflammatory response at the DC-administration site 37 was effective in promoting migration of administered DCs to lymphoid tissues. Further research and development of 'lymphoid tissue-directivity DC' vaccine based on these data and our results may greatly improve efficacy and lead to clinical application of DC-based immunotherapy.
Materials and methods
Cell lines and mice
A murine B16BL6 melanoma cell line (H-2 b ) was cultured in minimum essential medium supplemented with 7.5% fetal bovine serum (FBS) and antibiotics. The helper cell line, 293 cells, was grown in Dulbecco's modified Eagle medium supplemented with 10% FBS and antibiotics. CD8-OVA 1.3 cells, were kindly provided by Dr M Okabe (Genome Information Research Center, Osaka University, Suita, Japan). All mice were held under specific pathogen-free conditions and the experimental procedures were in accordance with the Osaka University guidelines for the welfare of animals in experimental neoplasia.
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Vectors
Replication-deficient AdRGD was based on the adenovirus serotype 5 backbone with deletions of E1 and E3 regions. The RGD sequence for av-integrin targeting was inserted into the HI loop of the fiber knob using a twostep method as described previously. 40 The expression cassette containing mouse CCR7 cDNA derived from pBluescript SK(+)/mCCR7 under the control of the cytomegalovirus promoter was inserted into the E1-deletion site to construct AdRGD-CCR7, using an improved in vitro ligation method as described previously. [40] [41] [42] Luciferase-expressing AdRGD (AdRGDLuc), OVA-expressing AdRGD (AdRGD-OVA), and gp100-expressing AdRGD (AdRGD-gp100) were constructed previously. [12] [13] [14] All recombinant AdRGDs were propagated in 293 cells, purified by two rounds of cesium chloride gradient ultracentrifugation, dialyzed, and stored at À801C. Titers of infective AdRGD particles were evaluated by the end-point dilution method using 293 cells.
Mouse bone marrow-derived DCs
DCs were prepared according to the method of Lutz et al, 43 with slight modification. Briefly, bone marrow cells flushed from the femurs and tibias of C57BL/6 or EGFPTg mice were seeded at 5 Â 10 6 cells per sterile 100-mm bacterial grade culture dish in 10 ml of RPMI 1640 containing 10% FBS, 40 ng/ml recombinant murine granulocyte/macrophage colony-stimulating factor (GM-CSF; kindly provided by KIRIN Brewery Co., Ltd, Tokyo, Japan), 50 mM 2-mercaptoethanol, and antibiotics. On day 3, another 10 ml of culture medium was added to the dish for medium replenishment. On day 6, 10 ml of the culture supernatant was collected and centrifuged at 1500 rpm for 5 min at room temperature, and the pellet was resuspended in 10 ml of fresh culture medium, and then returned to the original dish to conserve unattached cells. Eight-day-old DCs (nonadherent cells) were harvested and used as intact immature DCs in subsequent experiments. DCs cultured for another 24 h with media containing 1 mg/ml LPS (Nacalai Tesque, Inc., Kyoto, Japan) were used as phenotypically mature DCs.
Viral transduction into DCs
DCs were suspended at a concentration of 5 Â 10 6 cells/ ml in FBS-free RPMI 1640 and placed in a 15-ml conical tube. Each AdRGD was added at various MOI, the suspension was mixed well, and the tube was incubated at 371C for 2 h with occasional gentle agitation. The cells were washed three times with phosphate-buffered saline (PBS) and resuspended in a suitable solution.
Semiquantitative RT-PCR analysis CCR7/DCs, Luc/DCs, and mock DCs were cultured on 100-mm bacterial grade culture dishes in GM-CSF-free culture medium. Mouse CCR7 gene expression was assessed by semiquantitative RT-PCR analysis as follows. Total RNA was isolated from these cells and LPS/DCs using Sepasol-RNA I Super (Nacalai Tesque, Inc.) according to the manufacturer's instructions, and then RT proceeded for 60 min at 421C in a 50 ml reaction mixture containing 5 mg total RNA treated with DNase I, 10 ml 5 Â RT buffer, 5 mM MgCl 2 , 1 mM dNTP mix, 1 mM random primer (9-mer), 1 mM oligo(dT) 20 , and 100 U ReverTra Ace (TOYOBO Co., Ltd, Osaka, Japan). PCR amplification of the CCR7 and b-actin transcripts was performed in 50 ml of a reaction mixture containing 1 ml of RT material, 5 ml 10 Â PCR buffer, 1.25 U Taq DNA polymerase (TOYOBO Co., Ltd), 1.5 mM MgCl 2 , 0.2 mM dNTP, and 0.4 mM primers. The sequences of the specific primers were as follows; mouse CCR7: forward, 5 0 -aca gcg gcc tcc aga aga aca gcg g-3 0 ; reverse, 5 0 -tga cgt cat agg caa tgt tga gct g-3 0 ; mouse b-actin: forward, 5 0 -tgt gat ggt ggg aat ggg tca g-3 0 ; reverse, 5 0 -ttt gat gtc acg cac gat ttc c-3 0 . After denaturation for 2 min at 951C, 20 cycles of denaturation for 30 s at 951C, annealing for 30 s at 601C, and extension for 30 s at 721C were repeated and followed by completion for 4 min at 721C. The PCR product was electrophoresed through a 3% agarose gel, stained with ethidium bromide, and visualized under UV radiation. The expected PCR product sizes were 345 bp (CCR7) and 514 bp (b-actin). Quantification of PCR products was performed by densitometry analysis, and the relative CCR7 mRNA expression level was calculated as the ratio of the densitometric units of CCR7 PCR-products to the densitometric units of b-actin PCR products.
Flow cytometric analysis for mouse CCR7
CCR7/DCs and Luc/DCs were prepared by using corresponding vectors at 50 MOI. These transduced DCs, LPS/DCs, and mock DCs were cultured on 100-mm bacterial grade culture dishes in GM-CSF-free culture medium for 24 h. The cells (1 Â 10 6 ) were fixed by incubation for 10 min in 2% paraformaldehyde, and then incubated with 100 ml staining buffer (PBS containing 0.1% bovine serum albumin and 0.01% NaN 3 ) containing the anti-FcgRII/III monoclonal antibody (2.4G2; rat IgG 2b,k ; BD Biosciences, San Jose, CA, USA) to block nonspecific binding of the subsequently used antibody reagents. After 1 h, the cells were incubated overnight with anti-mouse CCR7 polyclonal antibody (goat Ig; ImmunoDetect Inc., Fayetteville, NY, USA) at a 1:10 dilution. Successively, cells were incubated for 2 h with FITC-conjugated rabbit anti-goat Ig (DakoCytomation, Kyoto, Japan) at a 1:100 dilution. Finally, 30 000 events of the stained cells were analyzed for mouse CCR7 protein expression by a FACSCalibur flow cytometer using CellQuest software (Becton Dickinson, Tokyo, Japan). Between all incubation steps, cells were washed three times with staining buffer.
In vitro chemotaxis assay CCR7/DCs, Luc/DCs, and mock DCs were cultured for 24 or 48 h in GM-CSF-free medium. Chemotactic activity of these DCs and LPS/DCs for CCL21 was measured by an in vitro chemotaxis assay across a polycarbonate membrane with 5-mm pores (Chemotaxicell-24; Kurabo Industries Ltd, Osaka, Japan). Recombinant murine CCL21 (PeproTech EC Ltd, London, England) dissolved in an assay medium (RPMI 1640 containing 0.5% bovine serum albumin and 20 mM HEPES) was added to a 24-well culture plate. DCs were suspended with the assay medium and were placed in a Chemotaxicell-24 installed on each well at 10 6 cells. Cell migration was allowed for 4 h at 371C in a 5% CO 2 atmosphere. Cells that migrated into the lower compartment were counted using a NucleoCountert (ChemoMetec, Allerød, Denmark), and the chemotactic activity was expressed in terms of 
Analysis of surface marker expression
All immunoreagents used in this experiment were purchased from BD Biosciences. CCR7/DCs and Luc/ DCs were prepared by using corresponding vectors at 50 MOI. At 24 h after transduction, immunophenotype of transduced DCs, LPS/DCs, and mock DCs was confirmed by flow cytometric analysis. Briefly, 10 6 cells in 100 ml staining buffer were incubated for 30 min on ice with the 2.4G2 monoclonal antibody to block nonspecific binding of the subsequently used immunoreagents. The cells were resuspended in 100 ml staining buffer and incubated for 30 min on ice using the manufacturer's recommended amounts of biotinylated monoclonal antibodies: 28-8-
and GL1 (anti-CD86). The cells were then resuspended in 100 ml staining buffer containing phycoerythrin-conjugated streptavidin at a 1:200 dilution, and nonspecific binding was measured using phycoerythrin-conjugated streptavidin alone. After incubation for 30 min on ice, 30 000 events of the stained cells were analyzed for surface phenotype by flow cytometry. Between all incubation steps, cells were washed three times with staining buffer.
Allogenic MLR C57BL/6 DCs were transduced with AdRGD-CCR7 or AdRGD-Luc at 50 MOI, and then cultured for 24 h. Allogenic naive T cells were purified from BALB/c splenocytes as nylon wool nonadherent cells, and were used as responder cells at 1 Â 10 5 cells/well in 96-well plates. CCR7/DCs, Luc/DCs, LPS/DCs, or mock DCs (stimulator cells) were inactivated by 50 mg/ml mitomycin C (MMC) for 30 min and added to responder cells in varying cell numbers. Cells were co-cultured in 100 ml RPMI 1640 supplemented with 10% FBS, 50 mM 2-mercaptoethanol, and antibiotics at 371C and 5% CO 2 for 3 days. Control wells contained either stimulator cells alone or responder cells alone. Cell cultures were pulsed with 5-bromo-2 0 -deoxyuridine (BrdU) during the last 18 h, and then proliferation of responder cells was evaluated by Cell Proliferation ELISA, BrdU (Roche Diagnostics Co., Indianapolis, IN, USA).
Antigen uptake assay
CCR7/DCs and Luc/DCs were prepared by using corresponding vectors at 50 MOI. These cells, LPS/ DCs, and mock DCs were cultured for 24 h, and then resuspended at 5 Â 10 6 cells/ml in ice-cold PBS containing 1 mg/ml FITC-dextran (MW: 77 000; Sigma Chemical Co., St Louis, MO, USA). The cells were incubated at 37 or 41C to determine background uptake. After 1 h, the cells were washed extensively with ice-cold PBS and analyzed by flow cytometry.
In vivo migration assay EGFP-Tg mouse-derived DCs were transduced with AdRGD-CCR7 or AdRGD-Luc at 50 MOI, and then cultured for 24 h. These transduced cells and mock DCs were intradermally injected into the left flank of wildtype C57BL/6 mice at 2 Â 10 6 cells/50 ml. After 2 days, the draining inguinal LNs were collected from these mice, and then a single-cell suspension was prepared. The isolated LN cells were blocked by 2.4G2 monoclonal antibody and stained by indirect immunofluorescence with biotinylated anti-CD11c monoclonal antibody (HL3; BD Biosciences) and PerCP-conjugated streptavidin. The stained cells were analyzed by flow cytometry acquiring 500 000 events, and the number of migrated DCs into draining LNs was calculated by multiplying the EGFP + CD11c + cell frequency by the total number of isolated LN cells.
Antigen-presentation assay C57BL/6 DCs were transduced with various combinations of AdRGD-OVA, AdRGD-CCR7, and AdRGD-Luc each at 25 MOI, and then seeded on a 96-well flat-bottom culture plate at a density of 1 Â 10 5 cells/well. These cells were co-cultured with 1 Â 10 5 cells/well CD8-OVA 1.3 cells at 371C for 20 h. The response of stimulated CD8-OVA 1.3 cells was assessed by determining the amount of IL-2 released into an aliquot of culture medium (100 ml) using a murine IL-2 ELISA KIT (Biosource International, Camarillo, CA, USA). Relative OVA-presentation level via MHC class I molecules in each transduced DC was calculated by the following formula: (relative OVA-presentation level) ¼ (IL-2 level in tested group)/(IL-2 level in group using DCs transduced with AdRGD-OVA alone) Â 100.
Tumor protection assay
DCs were transduced with AdRGD-CCR7 alone, AdRGD-gp100 alone, or a combination of AdRGD-CCR7 and AdRGD-gp100, each at 25 MOI, and then cultured for 24 h. These transduced DCs and mock DCs were intradermally injected into the left flank of C57BL/ 6 mice at 2 or 5 Â 10 5 cells/50 ml. At 1 week after the vaccination, 4 Â 10 5 B16BL6 melanoma cells were intradermally inoculated into the right flank of the mice. The major and minor axes of the tumor were measured using microcalipers, and the tumor volume was calculated by the following formula: (tumor volume; mm 3 ) ¼ (major axis; mm) Â (minor axis; mm) 2 Â 0.5236. The mice were euthanized when one of the two measurements was greater than 20 mm.
Eu-release assay and ELISPOT assay for B16BL6-specific CTLs
DCs were transduced with AdRGD-gp100 alone or a combination of AdRGD-CCR7 and AdRGD-gp100 at 25 MOI, and then cultured for 24 h. These transduced DCs and mock DCs were administered once intradermally into the left flank of C57BL/6 mice at 1, 2, or 5 Â 10 5 cells/50 ml. At 1 week after immunization, nonadherent splenocytes were prepared from these mice and re-stimulated in vitro using B16BL6 cells, which were cultured in media containing 100 U/ml recombinant murine IFN-g (PeproTech EC Ltd) for 24 h and inactivated with 50 mg/ml MMC at 371C for 30 min, at an effector/stimulator ratio of 10 in RPMI 1640 supplemented with 10% FBS, 50 mM 2-mercaptoethanol, and antibiotics. After 5 days, the splenocytes were collected and used as CTL effector cells. Target cells, IFN-g-stimulated B16BL6 cells, were Eu-labeled and a Eu-release assay CCR7-transduced DC vaccine N Okada et al was performed as described previously. 44 Cytolytic activity was determined using the following formula: (% of lysis) ¼ ((experimental Eu releaseÀspontaneous Eu release)/(maximum Eu releaseÀspontaneous Eu release)) Â 100. Spontaneous Eu release of the target cells was o10% of maximum Eu release by the detergent. In addition, IFN-g-producing cells in the re-stimulated splenocytes were detected by using Mouse IFN-g ELI-SPOT Kit (BD Biosciences) according to the manufacturer's instruction. Splenocytes from unimmunized mice had a frequency of three IFN-g spots/10
6 cells with or without re-stimulation.
